Arcturus Therapeutics
ARCT
11 hedge funds and large institutions have $31.6M invested in Arcturus Therapeutics in 2013 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
167% more capital invested
Capital invested by funds: $11.8M → $31.6M (+$19.8M)
83% more funds holding
Funds holding: 6 → 11 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sophrosyne Capital
New York
|
+$1.47M |
| 2 |
JP Morgan Chase
New York
|
+$743K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$185K |
| 4 |
EEG
E.E. Geduld
|
+$127K |
| 5 |
RFC
Russell Frank Company
Seattle,
Washington
|
+$72.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
-$1.26M |
| 2 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
-$159K |
| 3 |
U
UBS
Zurich,
Switzerland
|
-$3K |
ARCT Hedge Fund Activity: Q3 2013 in Review
11 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q3 2013, worth a combined $31.6M — up 167% from $11.8M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ARCT positions and 2 closed out — a net gain of 5 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Sophrosyne Capital, opening a new position worth an estimated $1.47M. The largest seller was Arrowgrass Capital Partners (US), exiting entirely with an estimated $1.26M sold.
- 11 institutional investors held Arcturus Therapeutics (ARCT) as of Q3 2013, up from 6 in Q2 2013.
- Funds reported $31.6M of Arcturus Therapeutics stock for Q3 2013, up 167% quarter-over-quarter.
- 7 funds opened new Arcturus Therapeutics positions in Q3 2013 and 2 closed out, a net change of +5 holders.
- The largest Arcturus Therapeutics buyer in Q3 2013 was Sophrosyne Capital, an estimated $1.47M added.
- The largest Arcturus Therapeutics seller in Q3 2013 was Arrowgrass Capital Partners (US), an estimated $1.26M sold.
Based on aggregated 13F filings for Q3 2013.